Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Phase of Trial: Phase III
Latest Information Update: 04 May 2017
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- Acronyms IDRIS
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.
- 07 Nov 2016 Planned End Date changed from 30 Jun 2020 to 1 Dec 2025.
- 07 Nov 2016 Planned primary completion date changed from 1 Dec 2022 to 1 Oct 2021.